Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of balcinrenone + dapagliflozin versus dapagliflozin in chronic heart failure with renal impairment
MOH_2024-03-07_013294Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of balcinrenone and dapagliflozin in heart failure (HF) and chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2024-03-07_013294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-07_013294.